Journal of Affective Disorders
Volume 84, Issue 1 , Pages 93-98 , January 2005

Mood, cognition and EEG changes during interferon α (alpha-IFN) treatment for chronic hepatitis C

  • Piero Amodio

      Affiliations

    • Dipartimento di Medicina Clinica e Sperimentale, Clinica Medica 5, Policlinico Universitario, via Giustiniani, 2, 35128, Padova, Italy
    • ,
  • Enrico N. De Toni

      Affiliations

    • Dipartimento di Medicina Clinica e Sperimentale, Clinica Medica 5, Policlinico Universitario, via Giustiniani, 2, 35128, Padova, Italy
    • ,
  • Luisa Cavalletto

      Affiliations

    • Dipartimento di Medicina Clinica e Sperimentale, Clinica Medica 5, Policlinico Universitario, via Giustiniani, 2, 35128, Padova, Italy
    • ,
  • Daniela Mapelli

      Affiliations

    • Dipartimento di Psicologia Generale, CIRMANMEC, Università di Padova, Italy
    • ,
  • Elisabetta Bernardinello

      Affiliations

    • Dipartimento di Medicina Clinica e Sperimentale, Clinica Medica 5, Policlinico Universitario, via Giustiniani, 2, 35128, Padova, Italy
    • ,
  • Franco Del Piccolo

      Affiliations

    • Dipartimento di Medicina Clinica e Sperimentale, Clinica Medica 5, Policlinico Universitario, via Giustiniani, 2, 35128, Padova, Italy
    • ,
  • Cristina Bergamelli

      Affiliations

    • Dipartimento di Neuroscienze, CIRMANMEC, Università di Padova, Italy
    • ,
  • Raffaella Costanzo

      Affiliations

    • Dipartimento di Neuroscienze, CIRMANMEC, Università di Padova, Italy
    • ,
  • Federica Bergamaschi

      Affiliations

    • Dipartimento di Neuroscienze, CIRMANMEC, Università di Padova, Italy
    • ,
  • Stefano Zanone Poma

      Affiliations

    • Dipartimento di Neuroscienze, CIRMANMEC, Università di Padova, Italy
    • ,
  • Liliana Chemello

      Affiliations

    • Dipartimento di Medicina Clinica e Sperimentale, Clinica Medica 5, Policlinico Universitario, via Giustiniani, 2, 35128, Padova, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 049 821 8679.
    • ,
  • Angelo Gatta

      Affiliations

    • Dipartimento di Medicina Clinica e Sperimentale, Clinica Medica 5, Policlinico Universitario, via Giustiniani, 2, 35128, Padova, Italy
    • Dipartimento di Psicologia Generale, CIRMANMEC, Università di Padova, Italy
    • Dipartimento di Neuroscienze, CIRMANMEC, Università di Padova, Italy
    • Regional Project on Chronic Liver Disease, Regione Veneto, Italy
    • ,
  • Giulia Perini

      Affiliations

    • Dipartimento di Neuroscienze, CIRMANMEC, Università di Padova, Italy

Received 6 July 2004 ,Revised 27 September 2004 ,Accepted 27 September 2004.

References 

  1. Amodio P, Marchetti P, Del Piccolo F, et al. Study on the Sternberg paradigm in cirrhotic patients without overt hepatic encephalopathy. Metab. Brain Dis. 1998;13:159–172
  2. Amodio P, Marchetti P, Del Piccolo F, et al. Spectral versus visual EEG analysis in mild hepatic encephalopathy. Clin. Neurophysiol. 1999;110:1334–1344
  3. Amodio P, Del Piccolo F, Marchetti P, et al. Clinical features and survival of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology. 1999;29:1662–1667
  4. Barrett G. Clinical application of event-related potentials in dementing illness: issues and problems. Int. J. Psychophysiol. 2000;37:49–53
  5. Beck AT, Word Ch, et al. An inventory for measuring depression. Arch. Gen. Psychiatry. 1961;4:561–571
  6. Belville S, Peretz I, Malefant D. Examination of the working memory components in normal aging and dementia of the Alzheimer type. Neuropsychologia. 1996;34:195–207
  7. Benton AL, Hamsher K. Multilingual Aphasia Examination. Iowa City: University of Iowa Press; 1976;
  8. Capuron L, Ravaud A. Prediction of the depressive effects of interferon alfa therapy by the patients initial affective state. N. Engl. J. Med. 1999;340:1370
  9. Capuron L, Ravaud A, Dantzer R. Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients. Psychosom. Med. 2001;63:376–386
  10. Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D, et al. Interferon-alpha-induced changes in tryptophan metabolism: relationship to depression and paroxetine treatment. Biol. Psychiatry. 2003;54:906–914
  11. Chemello L, Cavalletto L, Bernardinello E, et al. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J. Hepatol. 1995;23(Suppl. 2):8–12
  12. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am. J. Psychiatry. 2000;157:867–876
  13. Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics. 2003;44:104–112
  14. Exton MS, Baase J, Pithan V, Goebel MU, Schedlowski M. Neuropsychological performance and mood states following acute interferon-beta-1b administration in healthy males. Neuropsychobiology. 2002;45:199–204
  15. Fattovich G, Giustina G, Favarato S, et al. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J. Hepatol. 1996;24:38–47
  16. Hamilton M. The assessment of anxiety states by rating. Br. J. Med. Psychol. 1959;32:50–55
  17. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 1960;23:56–62
  18. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol. Psychiatry. 2002;7:942–947
  19. Hensley ML, Peterson B, Silver RT, et al. Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013. J. Clin. Oncol. 2000;18:1301–1308
  20. Hunt CM, Dominitz JA, Bute BP, et al. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Dig. Dis. Sci. 1997;42:2482–2486
  21. Kamei S, Sakai T, Matsuura M, et al. Alterations of quantitative EEG and mini-mental state examination in interferon-alpha-treated hepatitis C. Eur. Neurol. 2002;48:102–107
  22. Kraus MR, Shaefer A, Faller H, Csef H, Scheurlen M. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment. Pharmacol. Ther. 2002;16:1091–1099
  23. Kraus MR, Schäfer A, Faller H, Csef H, Scheurlen M. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J. Clin. Psychiatry. 2003;64:708–714
  24. Maes M, Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, et al. Treatment with interferon-alpha (alpha-IFN) of hepatitis induces lower serum dipeptidyl peptidase IV activity, which is related to alpha-IFN induced depressive and anxiety symptoms and immune activation. Mol. Psychiatry. 2001;6:475–480
  25. Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon alpha 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965
  26. Mondini S, Mapelli D, Vestri A, et al. Esame Neuropsicologico Breve (ENB). Padova: Raffaello Cortina; 2003;
  27. Mulder RT, Ang M, Chapman B, et al. Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C. J. Gastroenterol. Hepatol. 2000;15:300–303
  28. Otsubo T, Miyaoka H, Otsubo T, Kamijima K, Ishii M, Onuki M, et al. Depression from interferon therapy in patients with hepatitis C. Am. J. Psychiatry. 1999;156:1120
  29. Pariante CM, Orru MG, Baita A, et al. Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet. 1999;354:131–132
  30. Pavol MA, Meyers CA, Rexer JL, et al. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology. 1995;45:947–950
  31. Peterson LR, Peterson MJ. Short-term retention of individual verbal items. J. Exp. Psychol. 1959;68:193–198
  32. Quesada JR, Talpaz M, Rios A, et al. Clinical toxicity of interferons in cancer patients: a review. J. Clin. Oncol. 1986;4:234–243
  33. Reitan RM. Validity of the trail making test as an indicator of organic brain damage. Percept. Mot. Skills. 1958;8:271–276
  34. Rey A, Benton AL. Examen de afasia multilingue. Iowa City, IA: AJA Associates; 1991;
  35. Shaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, et al. Adherence and mental side effects during hepatitis C treatment with interferon alpha and ribavirin in psychiatric risk groups. Hepatology. 2003;37:443–451
  36. Shallice T, Evans ME. The involvement of the frontal lobes in cognitive estimation. Cortex. 1978;14:294–303
  37. Sheehan, D.V., Lecrubier, Y. 1994. Mini International Neuropsychiatric Interview (M.I.N.I.). University of South Florida Institute for Research in Psychiatry, Tampa, Florida and INSERM - Hopital de la Salpétrière, Paris, France.
  38. Smith A, Tyrrell D, Coyle K, et al. Effects of interferon alpha on performance in man: a preliminary report. Psychopharmacology. 1988;96:414–416
  39. Spielberg CD. Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press; 1983;Revised edition
  40. Sternberg S. Memory-scanning: mental processes revealed by reaction-time experiments. Am. Sci. 1969;57:421–457
  41. Stroop JR. Studies of interference in serial verbal reactions. J. Exp. Psychol. 1935;18:643–662
  42. Trask PC, Esper P, Riba M, et al. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J. Clin. Oncol. 2000;18:2316–2326
  43. Valentine AD, Meyers CA, Kling MA, et al. Mood and cognitive side effects of interferon-alpha therapy. Semin. Oncol. 1998;25:39–47
  44. von Ammon CS. Depression in the medically ill. Critical issues in diagnostic assessment. Psychosomatics. 1995;36:48–59
  45. Wechsler D. A standardized memory scale for clinical use. J. Psychol. 1945;19:87–95

PII: S0165-0327(04)00317-9

doi: 10.1016/j.jad.2004.09.004

Journal of Affective Disorders
Volume 84, Issue 1 , Pages 93-98 , January 2005

Article Tools

* Image Usage & Resolution